Current and emerging therapies in atheroprotection

Stephen Nicholls, Rishi Puri

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Other

Abstract

BACKGROUND The global epidemic of cardiovascular disease (CVD) continues to rise, with atherosclerotic CVD remaining the lead cause of morbidity and mortality worldwide, comprising of 29% of all global deaths in 2003. A majority of these deaths were directly caused by coronary artery disease (CAD) or strokes. It is estimated that up to 50% of all deaths and disability due to CAD and strokes could be curtailed by a number of lifestyle and therapeutic approaches that directly target major cardiovascular risk factors. Atherosclerosis is a systemic disease process involving multiple vascular territories. The presence of established vascular disease, regardless of the territory involved, portends the greatest risk of incident cardiovascular events. The prevalence of asymptomatic coronary stenoses of greater than 50% angiographic severity in non-disabling ischaemic stroke patients has recently been estimated to be 20%, and those patients afflicted with peripheral arterial disease have a probability of death due to CAD and stroke of 55% and 11% respectively. Given the significant systemic plaque burden in these patients coupled with corresponding high event rates, various anti-atherosclerotic and vascular protective therapies have the potential to significantly lower absolute clinical event rates. PATHOLOGY Atherosclerosis is a chronic inflammatory condition, characterised by the accumulation of inflammatory cells, lipid and apoptotic material within the arterial wall. The endothelial cell layer, a single cell layer lining the lumen of the vasculature, serves to regulate permeability of the arterial wall, vascular tone and tendency for thrombus formation.

Original languageEnglish
Title of host publicationMechanisms of Vascular Disease
Subtitle of host publicationA Reference Book for Vascular Specialists
EditorsRobert Fitridge, Matthew Thompson
PublisherUniversity of Adelaide Press
Pages79-102
Number of pages24
ISBN (Electronic)9781922064004
ISBN (Print)9780987171825
DOIs
Publication statusPublished - 1 Jan 2011

Cite this

Nicholls, S., & Puri, R. (2011). Current and emerging therapies in atheroprotection. In R. Fitridge, & M. Thompson (Eds.), Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists (pp. 79-102). University of Adelaide Press. https://doi.org/10.1017/UPO9781922064004.006
Nicholls, Stephen ; Puri, Rishi. / Current and emerging therapies in atheroprotection. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. editor / Robert Fitridge ; Matthew Thompson. University of Adelaide Press, 2011. pp. 79-102
@inbook{bb0edd0ad0674fa488210b9c316edc2c,
title = "Current and emerging therapies in atheroprotection",
abstract = "BACKGROUND The global epidemic of cardiovascular disease (CVD) continues to rise, with atherosclerotic CVD remaining the lead cause of morbidity and mortality worldwide, comprising of 29{\%} of all global deaths in 2003. A majority of these deaths were directly caused by coronary artery disease (CAD) or strokes. It is estimated that up to 50{\%} of all deaths and disability due to CAD and strokes could be curtailed by a number of lifestyle and therapeutic approaches that directly target major cardiovascular risk factors. Atherosclerosis is a systemic disease process involving multiple vascular territories. The presence of established vascular disease, regardless of the territory involved, portends the greatest risk of incident cardiovascular events. The prevalence of asymptomatic coronary stenoses of greater than 50{\%} angiographic severity in non-disabling ischaemic stroke patients has recently been estimated to be 20{\%}, and those patients afflicted with peripheral arterial disease have a probability of death due to CAD and stroke of 55{\%} and 11{\%} respectively. Given the significant systemic plaque burden in these patients coupled with corresponding high event rates, various anti-atherosclerotic and vascular protective therapies have the potential to significantly lower absolute clinical event rates. PATHOLOGY Atherosclerosis is a chronic inflammatory condition, characterised by the accumulation of inflammatory cells, lipid and apoptotic material within the arterial wall. The endothelial cell layer, a single cell layer lining the lumen of the vasculature, serves to regulate permeability of the arterial wall, vascular tone and tendency for thrombus formation.",
author = "Stephen Nicholls and Rishi Puri",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/UPO9781922064004.006",
language = "English",
isbn = "9780987171825",
pages = "79--102",
editor = "Fitridge, {Robert } and Thompson, {Matthew }",
booktitle = "Mechanisms of Vascular Disease",
publisher = "University of Adelaide Press",

}

Nicholls, S & Puri, R 2011, Current and emerging therapies in atheroprotection. in R Fitridge & M Thompson (eds), Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. University of Adelaide Press, pp. 79-102. https://doi.org/10.1017/UPO9781922064004.006

Current and emerging therapies in atheroprotection. / Nicholls, Stephen; Puri, Rishi.

Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. ed. / Robert Fitridge; Matthew Thompson. University of Adelaide Press, 2011. p. 79-102.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Other

TY - CHAP

T1 - Current and emerging therapies in atheroprotection

AU - Nicholls, Stephen

AU - Puri, Rishi

PY - 2011/1/1

Y1 - 2011/1/1

N2 - BACKGROUND The global epidemic of cardiovascular disease (CVD) continues to rise, with atherosclerotic CVD remaining the lead cause of morbidity and mortality worldwide, comprising of 29% of all global deaths in 2003. A majority of these deaths were directly caused by coronary artery disease (CAD) or strokes. It is estimated that up to 50% of all deaths and disability due to CAD and strokes could be curtailed by a number of lifestyle and therapeutic approaches that directly target major cardiovascular risk factors. Atherosclerosis is a systemic disease process involving multiple vascular territories. The presence of established vascular disease, regardless of the territory involved, portends the greatest risk of incident cardiovascular events. The prevalence of asymptomatic coronary stenoses of greater than 50% angiographic severity in non-disabling ischaemic stroke patients has recently been estimated to be 20%, and those patients afflicted with peripheral arterial disease have a probability of death due to CAD and stroke of 55% and 11% respectively. Given the significant systemic plaque burden in these patients coupled with corresponding high event rates, various anti-atherosclerotic and vascular protective therapies have the potential to significantly lower absolute clinical event rates. PATHOLOGY Atherosclerosis is a chronic inflammatory condition, characterised by the accumulation of inflammatory cells, lipid and apoptotic material within the arterial wall. The endothelial cell layer, a single cell layer lining the lumen of the vasculature, serves to regulate permeability of the arterial wall, vascular tone and tendency for thrombus formation.

AB - BACKGROUND The global epidemic of cardiovascular disease (CVD) continues to rise, with atherosclerotic CVD remaining the lead cause of morbidity and mortality worldwide, comprising of 29% of all global deaths in 2003. A majority of these deaths were directly caused by coronary artery disease (CAD) or strokes. It is estimated that up to 50% of all deaths and disability due to CAD and strokes could be curtailed by a number of lifestyle and therapeutic approaches that directly target major cardiovascular risk factors. Atherosclerosis is a systemic disease process involving multiple vascular territories. The presence of established vascular disease, regardless of the territory involved, portends the greatest risk of incident cardiovascular events. The prevalence of asymptomatic coronary stenoses of greater than 50% angiographic severity in non-disabling ischaemic stroke patients has recently been estimated to be 20%, and those patients afflicted with peripheral arterial disease have a probability of death due to CAD and stroke of 55% and 11% respectively. Given the significant systemic plaque burden in these patients coupled with corresponding high event rates, various anti-atherosclerotic and vascular protective therapies have the potential to significantly lower absolute clinical event rates. PATHOLOGY Atherosclerosis is a chronic inflammatory condition, characterised by the accumulation of inflammatory cells, lipid and apoptotic material within the arterial wall. The endothelial cell layer, a single cell layer lining the lumen of the vasculature, serves to regulate permeability of the arterial wall, vascular tone and tendency for thrombus formation.

UR - http://www.scopus.com/inward/record.url?scp=84941566224&partnerID=8YFLogxK

U2 - 10.1017/UPO9781922064004.006

DO - 10.1017/UPO9781922064004.006

M3 - Chapter (Book)

SN - 9780987171825

SP - 79

EP - 102

BT - Mechanisms of Vascular Disease

A2 - Fitridge, Robert

A2 - Thompson, Matthew

PB - University of Adelaide Press

ER -

Nicholls S, Puri R. Current and emerging therapies in atheroprotection. In Fitridge R, Thompson M, editors, Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. University of Adelaide Press. 2011. p. 79-102 https://doi.org/10.1017/UPO9781922064004.006